Nanobiotix Market Cap ($1.43 Billion)
Market Cap & Net Worth: Nanobiotix (NBTX)
Nanobiotix market cap. Nanobiotix (NASDAQ:NBTX) has a market capitalization of $1.43 Billion ($1.43 Billion) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7154 globally and #2204 in its home market, demonstrating a -4.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanobiotix's stock price $28.11 by its total outstanding shares 50811344 (50.81 Million). Also see Nanobiotix operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Nanobiotix Market Cap History (2020–2026)
Nanobiotix market cap history from 2020 to 2026. Data shows growth from $838.39 Million to $1.43 Billion (8.93% CAGR). Check Nanobiotix share price for real-time trading data and today's change.
Index Memberships
Nanobiotix is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.05% | #205 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #794 of 3165 |
Weight: Nanobiotix's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nanobiotix Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanobiotix's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Nanobiotix equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
39.63x
Nanobiotix's market cap is 39.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $838.39 Million | $2.33 Million | -$33.59 Million | 360.60x | N/A |
| 2021 | $411.57 Million | $2.65 Million | -$47.00 Million | 155.49x | N/A |
| 2022 | $186.48 Million | $4.78 Million | -$57.04 Million | 39.04x | N/A |
| 2023 | $369.91 Million | $36.21 Million | -$39.70 Million | 10.22x | N/A |
| 2024 | $145.83 Million | $-7.19 Million | -$68.13 Million | -20.28x | N/A |
| 2025 | $1.17 Billion | $29.64 Million | -$23.96 Million | 39.63x | N/A |
Competitor Companies of NBTX by Market Capitalization
Companies near Nanobiotix in the global market cap rankings as of November 3, 2026. Also see NBTX total assets for a full breakdown of the balance sheet.
Key companies related to Nanobiotix by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Nanobiotix (2020–2026)
Market capitalization of Nanobiotix from 2020 to today. Between 2020 and today, Nanobiotix's market cap moved from $838.39 Million to $ 1.43 Billion, with a yearly change of 8.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.43 Billion | +21.58% |
| 2025 | $1.17 Billion | +705.57% |
| 2024 | $145.83 Million | -60.58% |
| 2023 | $369.91 Million | +98.37% |
| 2022 | $186.48 Million | -54.69% |
| 2021 | $411.57 Million | -50.91% |
| 2020 | $838.39 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Nanobiotix was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.43 Billion USD |
| MoneyControl | $1.43 Billion USD |
| MarketWatch | $1.43 Billion USD |
| marketcap.company | $1.43 Billion USD |
| Reuters | $1.43 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small … Read more